The Latest Cardiac and Vascular News
PARIS–(BUSINESS WIRE)–TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced it has closed a Series C round of financing, raising €50 million from new and existing international investors. Cathay Health, affiliated to global investment firm Cathay Capital, led new investors and joined other institutional and individual backers […]
IDE Approval Clears Path to U.S. Clinical Trial Launch for Vascular Sealant PARIS–(BUSINESS WIRE)–TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, announced today it has received approval from the U.S. Food and Drug Administration for its Investigational Device Exemption application for its vascular sealant. The approval […]
PARIS–(BUSINESS WIRE)–TISSIUM, a privately-owned life science company developing fully synthetic, biomorphic programmable polymers, announced today the publication of its manuscript detailing preclinical and clinical evaluations of SETALIUMTM Vascular Sealant, the company’s first synthetic, biodegradable, on-demand, light-activated sealant. The results of these evaluations, published in The Journal of Cardiovascular Surgery on May 10th, 2019, […]
